Apr 19, 2016

Posted by in Biotech Stocks | 0 Comments

Trending Stocks: Pacific Biosciences of California Inc (NASDAQ:PACB), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Kite Pharma Inc (NASDAQ:KITE)

Trending Stocks: Pacific Biosciences of California Inc (NASDAQ:PACB), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Kite Pharma Inc (NASDAQ:KITE)

Pacific Biosciences of California Inc (NASDAQ:PACB) stock is at $9.10, up +4.24 percent from its previous close of $8.73. The stock opened the session at $8.68 and touched its highest price point at $9.13. The company’s stock’s lowest price point for the session stood at $8.43. Its yesterday’s volume was 1.56 million shares in comparison to its usual trading volume of 1.72 million shares.

Pacific Biosciences of California Inc (NASDAQ:PACB) on April 5, 2016 announced that the company will hold its quarterly conference call to discuss its First Quarter 2016 Financial Results on Thursday, April 21, 2016, at 4:30pm Eastern Time.

Pacific Biosciences of California, Inc. (PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock is at $7.94, down -0.38 percent from its previous close of $7.97. Its yesterday’s volume was 1.68 million shares in comparison to its usual trading volume of 1.97 million shares. Previous 5 days graph demonstrated a negative move of -6.48%. Its quarterly performance remained green with the percentage of 28.90, while its year to date performance showed that the stock advanced overall 0.51%.

Leica Biosystems and Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced on April 14, 2016, a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. The assays will be designed using Advanced Cell Diagnostics’ (ACD’s) RNAscope technology and will be processed on Leica Biosystems’ BOND clinical advanced staining systems.

The initial focus of this partnership will be the development of a companion diagnostic assay for Merrimack’s seribantumab, or MM-121, an investigational therapy. Seribantumab is a fully human, monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin (HRG). Heregulin-driven ErbB3 signaling identifies a unique, more difficult to treat cancer phenotype characterized by increased tumor growth and increased resistance to targeted, cytotoxic and anti-endocrine therapies. Seribantumab is being investigated primarily in combination settings, to block HRG activated ErbB3 signaling in order to enhance the anti-tumor effect of the combination therapy partner.

Kite Pharma Inc (NASDAQ:KITE) traded in the range of $46.62 and $48.99 in its previous trading session. The stock recorded the volume of 1.7 million shares so far, in comparison its average daily trading volume of 1.21 million shares. Company’s year to date performance remained declining as it lost almost -22.22%. The stock opened at $46.93 and its closing price for the day was $47.93, down -4.41 percent from its previous close.

Kite Pharma Inc (NASDAQ:KITE) on April 16, 2016 announced that the cell therapy manufacturing facilities at the National Cancer Institute (NCI) are undergoing a voluntary internal review by the National Institutes of Health (NIH) in connection with the NIH’s review of all NCI facilities involving sterile material.

Kite and the NCI are advancing multiple clinical trials under Cooperative Research and Development Agreements (CRADAs) for the treatment of both hematological and solid tumors.  Patients currently enrolled in the ongoing NCI clinical trials will receive therapy, but no new patients will be enrolled until the review is complete.  The NCI’s ongoing clinical trial of a fully human anti-CD19 chimeric antigen receptor (CAR)-based product candidate is not affected by the review.

The review of the NCI’s manufacturing facilities is not related to KTE-C19 or Kite’s manufacturing capabilities.  Kite’s four ongoing multi-center clinical trials of KTE-C19 are continuing.  Kite also remains on track to file an IND with the FDA by the end of this year for a TCR-based product candidate targeting a MAGE antigen for the treatment of certain solid tumors.

 

Comments are closed.